Day & Ennis’s Gilead Sciences GILD Stock Holding History

Day & Ennis’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,547	Closed	-$202K	–	83
2016 Q3	$202K	Buy	+2,547	New	+$207K	0.21%	66
2016 Q2	–	Sell	-2,309	Closed	-$212K	–	74
2016 Q1	$212K	Buy	2,309 +3	+0.1%	+$271	0.23%	58
2015 Q4	$233K	Buy	+2,306	New	+$240K	0.26%	56

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Day & Ennis's GILD Position: Q4 2016 in Review

Day & Ennis sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 2,547 shares — an estimated $202K sold.

Day & Ennis first reported a position in GILD in Q4 2015 and held it in 3 quarters. The position peaked at $233K in Q4 2015. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Day & Ennis reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
Day & Ennis sold 2,547 Gilead Sciences shares in Q4 2016, an estimated $202K.
Day & Ennis first reported a position in Gilead Sciences in Q4 2015 and held it in 3 quarters.
Day & Ennis's Gilead Sciences position peaked at $233K in Q4 2015.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Day & Ennis's 13F filing for Q4 2016, filed 13 Feb 2017.